Tarsons Products Limited
Healthcare›Healthcare›Healthcare Equipment & Supplies›Medical Equipment & Supplies
Key metrics
Price as of 2026-07-20
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2021 | Mar 2022Standalone only | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 71 Cr | 85 Cr | 191 Cr | 296 Cr | 85 Cr | 184 Cr | 96 Cr | 113 Cr | 91 Cr | 102 Cr | 108 Cr | 121 Cr |
| Operating expenses (approx.) | 35 Cr | 38 Cr | 113 Cr | 185 Cr | 63 Cr | 129 Cr | 65 Cr | 72 Cr | 63 Cr | 69 Cr | 69 Cr | 80 Cr |
| EBITDA | 36 Cr | 47 Cr | 78 Cr | 111 Cr | 22 Cr | 55 Cr | 30 Cr | 41 Cr | 28 Cr | 33 Cr | 39 Cr | 41 Cr |
| OPM % | 50.4% | 55.2% | 40.7% | 37.5% | 25.5% | 30.1% | 31.9% | 36.2% | 30.7% | 32.5% | 35.8% | 34.0% |
| Other income | 2 Cr | 3 Cr | 8 Cr | 11 Cr | 3 Cr | 11 Cr | 0.85 Cr | 4 Cr | 3 Cr | 6 Cr | 8 Cr | 7 Cr |
| Interest | 1 Cr | 0.45 Cr | 6 Cr | 10 Cr | 4 Cr | 9 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 6 Cr | 6 Cr |
| Depreciation | 5 Cr | 7 Cr | 28 Cr | 40 Cr | 11 Cr | 25 Cr | 17 Cr | 20 Cr | 20 Cr | 22 Cr | 25 Cr | 29 Cr |
| Profit before tax | 29 Cr | 39 Cr | 44 Cr | 61 Cr | 6 Cr | 21 Cr | 8 Cr | 16 Cr | 3 Cr | 6 Cr | 8 Cr | 6 Cr |
| Tax % | 25.7% | 24.9% | 26.1% | 29.8% | 36.4% | 32.5% | 34.7% | 34.5% | 41.2% | 40.6% | 32.9% | 27.5% |
| Net profit | 21 Cr | 29 Cr | 32 Cr | 43 Cr | 4 Cr | 14 Cr | 5 Cr | 10 Cr | 2 Cr | 3 Cr | 5 Cr | 4 Cr |
| EPS (₹) | ₹4.14 | ₹5.69 | ₹6.08 | ₹8.01 | ₹0.75 | ₹2.69 | ₹0.99 | ₹1.92 | ₹0.34 | ₹0.62 | ₹0.95 | ₹0.79 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2022Standalone only | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 301 Cr | 296 Cr | 392 Cr | 423 Cr | Sign in for TTM |
| Operating expenses (approx.) | 140 Cr | 197 Cr | 266 Cr | 282 Cr | Sign in for TTM |
| EBITDA | 161 Cr | 100 Cr | 127 Cr | 141 Cr | Sign in for TTM |
| OPM % | 53.6% | 33.7% | 32.3% | 33.4% | Sign in for TTM |
| Other income | 8 Cr | 11 Cr | 16 Cr | 24 Cr | Sign in for TTM |
| Interest | 4 Cr | 10 Cr | 19 Cr | 23 Cr | Sign in for TTM |
| Depreciation | 22 Cr | 40 Cr | 62 Cr | 97 Cr | Sign in for TTM |
| Profit before tax | 135 Cr | 61 Cr | 45 Cr | 22 Cr | Sign in for TTM |
| Tax % | 25.4% | 29.8% | 33.6% | 34.6% | Sign in for TTM |
| Net profit | 101 Cr | 43 Cr | 30 Cr | 14 Cr | Sign in for TTM |
| EPS (₹) | ₹19.46 | ₹8.01 | ₹5.60 | ₹2.69 | Sign in for TTM |
| Dividend payout % | 0.0% | 0.0% | 35.7% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2022Standalone only | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 11 Cr | 11 Cr | 11 Cr | 11 Cr |
| Reserves | 479 Cr | 602 Cr | 620 Cr | 624 Cr |
| Borrowings | 22 Cr | 257 Cr | 124 Cr | 173 Cr |
| Other liabilities | 33 Cr | 103 Cr | 326 Cr | 378 Cr |
| Total liabilities | 544 Cr | 972 Cr | 1,080 Cr | 1,186 Cr |
| Fixed assets (net) | 188 Cr | 248 Cr | 455 Cr | 657 Cr |
| CWIP | 32 Cr | 267 Cr | 233 Cr | 159 Cr |
| Investments | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
| Other assets | 245 Cr | 235 Cr | 243 Cr | 266 Cr |
| Total assets | 544 Cr | 972 Cr | 1,080 Cr | 1,186 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2022Standalone only | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operating activity | 83 Cr | 103 Cr | 114 Cr | 118 Cr |
| Cash from investing | -138 Cr | -285 Cr | -145 Cr | -130 Cr |
| Cash from financing | 130 Cr | 136 Cr | 39 Cr | 9 Cr |
| Net cash flow | 75 Cr | -47 Cr | 8 Cr | -2 Cr |
| Free cash flow (OCF − Capex) | -49 Cr | -82 Cr | -37 Cr | -7 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2022Standalone only | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | 28.4% | 6.8% | 8.5% | 5.5% |
| ROE % | 20.6% | 0.0% | 0.0% | 0.0% |
| Debtor days | 79 | 96 | — | — |
| Inventory days | 431 | 745 | 573 | 647 |
| Days payable | 68 | 85 | — | — |
| Cash conversion cycle | 442 | 757 | 573 | 647 |
| Debt / equity | 0.04 | 0.42 | 0.20 | 0.27 |
| Current ratio | 7.00 | 1.10 | 1.38 | 1.01 |
| Net debt / EBITDA | 0.00 | 2.40 | 0.78 | 1.06 |
Compare with peers
Loading peers…